---
schema_version: "secwatch.filing_event.v1"
accession: "0001237831-25-000029"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:23:19.849952+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Globus Medical Q3 revenue $769M (+23% YoY); raises FY2025 EPS guidance to $3.75-$3.85

## Summary
- Net sales $769.0M, +22.9% YoY; base business (ex-Nevro) $669.8M (+7.0%); Nevro contributed $99.3M.
- GAAP diluted EPS $0.88, up 134% YoY; non-GAAP diluted EPS $1.18, up 42.6% YoY.
- FY2025 revenue guidance raised to $2.86-$2.90B; non-GAAP EPS raised to $3.75-$3.85 (prev $3.00-$3.30).
- Record non-GAAP free cash flow of $213.9M in Q3; share repurchases of $40M in Q3, total $255.5M YTD.
- Nevro acquisition now expected to be accretive to earnings in 2025.

## SEC filing metadata
- accession: 0001237831-25-000029
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/0001237831-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000123783125000029/gmed-20251106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001237831-25-000029
- JSON: https://secwatch.observer/filing/0001237831-25-000029.json
- Plain text: https://secwatch.observer/filing/0001237831-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.